Stig Östlund

torsdag, december 08, 2011

NEJM: Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection



/Swedish/ Tuberculos orsakar årligen nära 2 miljoner människors dödsfall. Enligt WHO är 1,8 miljarder människor infekterade av bakterien Mycobacterium tuberculosis. Och i vårt land har vi fått tillbaka sjukdomen. Rätta mig om jag har uppfattat siffror felaktigt.


Background


Treatment of latent Mycobacterium tuberculosis infection is an essential component of tuberculosis control and elimination. The current standard regimen of isoniazid for 9 months is efficacious but is limited by toxicity and low rates of treatment completion.

Methods

We conducted an open-label, randomized noninferiority trial comparing 3 months of directly observed once-weekly therapy with rifapentine (900 mg) plus isoniazid (900 mg) (combination-therapy group) with 9 months of self-administered daily isoniazid (300 mg) (isoniazid-only group) in subjects at high risk for tuberculosis. Subjects were enrolled from the United States, Canada, Brazil, and Spain and followed for 33 months. The primary end point was confirmed tuberculosis, and the noninferiority margin was 0.75%.

Results ... /cont. >>/ http://www.nejm.org/doi/full/10.1056/NEJMoa1104875?query=BUL

Bloggarkiv